NYSE American · Biotechnology · USD

Matinas BioPharma Holdings, Inc. (MTNB) Stock Analysis

Matinas BioPharma Holdings, Inc. (MTNB) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

MTNB

$1.52

−$0.18 (−10.59%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MTNB with… →

MTNB Key Statistics

As of Oct 21, 2026

Trading

Open: $1.69
Previous Close: $1.70
Day's Range: 1.47–1.69
52-Week Range: 1.47–25.05
Volume: 19.87K
Beta: 2.08

Valuation

Market Cap: $1.49M
P/E Ratio: unprofitable
EPS (ttm): −17.55

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$10.35M
Shares Outstanding: 979.52K
1-Year Return: −7.88%

Dividend and dates

Avg Volume: 390.71K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MTNB closed at $1.52, −7.88% over 1 year.

Matinas BioPharma Holdings, Inc. (MTNB) has a market capitalization of $1.49M.

In fiscal 2025, MTNB reported revenue of $0.00.

MTNB Stock Return by Calendar Year

Matinas BioPharma Holdings, Inc. (MTNB) 10-year return: what $10,000 became

1 year: $10,000 $9,212; −7.88%
5 years: $10,000 $260; −97.40%
10 years: $10,000 $203; −97.97%

If you had invested $10,000 in Matinas BioPharma Holdings, Inc. (MTNB) 10 years ago, at the close on October 21, 2016, it would have been worth $203 at the close on October 21, 2026: −97.97% in total, −32.29% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+281.51%−95.28%+159.39%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+159.39%
2025	+14.90%
2024	−95.28%
2023	−56.80%
2022	−50.50%
2021	−25.74%
2020	−40.09%
2019	+281.51%
2018	−48.71%
2017	−17.14%
2016 (partial year)	+115.38%

As of October 21, 2026.

MTNB Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$10.35M	—
2024	$0.00	−$24.25M	—
2023	$1.10M	−$22.94M	−2,093.2%
2022	$3.19M	−$21.00M	−658.6%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$6.96M	−$10.35M	—
2024	$0.00	—	−$20.16M	−$24.25M	—
2023	$1.10M	—	−$23.77M	−$22.94M	−2,093.2%
2022	$3.19M	—	−$24.59M	−$21.00M	−658.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Matinas BioPharma Holdings, Inc. (MTNB) carries a market capitalisation of $1.49M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 2.

The 52-week range on file runs from $1.47 to $25.05. The most recent close on file for MTNB is $1.52, dated October 21, 2026. That is −$0.18 (−10.59%) against the previous close. The latest close sits 3.45% above that 52-week low.

Financial Health

In fiscal 2025, Matinas BioPharma Holdings, Inc. reported revenue of $0.00. The same year closed with a net loss of $10.35M. Earnings per share on a trailing basis come to −17.55.

Across the 4 fiscal years on file, revenue moves from $3.19M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is −7.88%. Across 10 years the annualized return works out at −32.29%. Beta against the wider market is reported at 2.08. Daily returns over the trailing 10 years annualize to a volatility of 558.1%.

Growth & Income

The record shows no dividend for MTNB.

So far in 2026 the total return is +159.39%. The strongest complete calendar year on file is 2019 at +281.51%; the weakest is 2024 at −95.28%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Matinas BioPharma Holdings, Inc. (MTNB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Matinas BioPharma Holdings, Inc.	MTNB	$1.49M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Matinas BioPharma Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Visit website →